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Abstract 
Background: We aimed to determine the association between nonalcoholic fatty liver disease (NAFLD) and diabetes 
risk among body size phenotypes which was based on cross-classification of body mass index (BMI) categories (nor-
mal or overweight/obesity) and metabolic status (metabolically health or metabolically at-risk).
Methods: We conducted a cross-sectional analysis using a cohort of 10,761 apparently healthy Chinese adults who 
underwent comprehensive health checkups including abdominal ultrasonography. Subjects were classified as meta-
bolically at-risk by having any two of the following, consistent with the Adult Treatment Panel-III metabolic syndrome 
definition: (1) systolic/diastolic blood pressure ≥130/85 mmHg, (2) triglycerides ≥1.7 mmol/L, (3) fasting blood glu-
cose ≥5.6 mmol/L, (4) HDL-cholesterol ≥1.0/1.3 mmol/L for men/women.
Results: Among participants without metabolically at-risk, multivariate-adjusted odds ratios (ORs) for diabetes from 
NAFLD compared with those without NAFLD in the normal-weight (BMI <23 kg/m2) and overweight/obese (BMI 
≥23 kg/m2) group were 2.10 (1.85–3.93) and 1.85 (1.35–2.53), respectively. Among participants with metabolically 
at-risk, the significant association between NAFLD and diabetes was lost, regardless of obesity status. There were 
only 27.1 % subjects with the presence of the three factors (overweight/obesity, NAFLD, and metabolically at-risk) 
occurring together, while the three factors occurring together was common (56.16 %) in diabetic individuals. The 
multivariate-adjusted ORs for diabetes were 1.1 (0.61–1.98) for overweight/obesity, 2.23 (1.05–5.14) for NAFLD, and 
8.04 (5.0–12.09) for metabolically at-risk. The OR for the presence of all the three factors occurring together was 23.22 
(13.96–38.63).
Conclusions: NAFLD was associated with diabetes risk among participants without metabolically at-risk. The cluster-
ing of overweight/obesity, NAFLD, and metabolically at-risk is common in diabetic subjects and strikingly and mark-
edly increases the diabetes risk.
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Background
Along with the increasing westernization of diet, physi-
cal inactivity, and the obesity epidemic [1], the worldwide 
prevalence of nonalcoholic fatty liver disease (NAFLD) 
is increasing rapidly, affecting between 15 and 30  % of 
adults [2, 3]. NAFLD is characterized by significant lipid 
deposits in the liver in patients with absence of excessive 
alcohol consumption. It has been considered as the 
hepatic manifestation of metabolic syndrome. Although 
obesity has contributed substantially to the burden of 
NAFLD, approximately 15  % of non-obese individuals 
may be encountered with NAFLD [4]. Clinic significance 
of NAFLD has been evaluated in non-obese patients [5–
7]. Some data show that NAFLD is independently associ-
ated with insulin resistance [5, 6] and metabolic disorders 
[7] in normal-weight individuals. A recent study suggests 
that the associations between NAFLD and metabolic 
disorders differ between non-obese and obese patients, 
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with the associations stronger in non-obese than in obese 
individuals [8]. On the other hand, components of meta-
bolic syndrome (such as hyperglycemia, dyslipidemia, or 
hypertension) are intimately related to the development 
of NAFLD [9, 10]. However, NAFLD is not a rare disease 
in persons without such risk factors [9]. Evidence shows 
that NAFLD is only associated with increased arterial 
stiffness [11] or carotid intima-media thickness [12] in 
the presence of metabolic risk factors. However, data also 
demonstrate that NAFLD forecasts an increased risk of 
cardiovascular disease (CVD) [13] independent of meta-
bolic syndrome. Taken together, the clinic significance of 
NAFLD may vary both by the obesity status and meta-
bolic status. Body mass index (BMI) is a poor indicator 
of body fat distribution, as evidenced by the occurrence 
of the variation in the burden of metabolic disorders, 
diabetes, and CVD among individuals with similar BMI 
[14]. The concomitant presence of body size and meta-
bolic status (that is, body size phenotype) can provide 
information on the distribution of body fat [15]. Excess 
visceral or ectopic fat accumulation can modulate cardio-
metabolic risk due to their greater endocrine activity [16, 
17]. Emerging evidence show that visceral or ectopic fat 
accumulation is a strong correlate of NAFLD [18]. Until 
now, few studies have examined CVD risk factors and 
diabetes risk associated with NAFLD among body size 
phenotypes.
Hence, we aim to evaluate the association of NAFLD 




The study participants were Chinese employees and 
retired workers aged 20–100 years from the Wuhan Iron 
and Steel Company (WISCO), which is one of the larg-
est iron and steel companies in China. In WISCO, the 
Industrial Safety and Health Law requires employees and 
retired workers to receive periodic health evaluations at 
the WISCO General Hospital (Wuhan, China). The pre-
sent cohort included all employees and retired work-
ers who received a comprehensive health examination 
(including abdominal ultrasonography) at the Healthcare 
system, WISCO general Hospital, between June 2008 and 
December 2010 (n = 15,753).
All subjects were asked to complete a standard ques-
tionnaire that gathered information on age, sex, ciga-
rette smoking and alcohol consumption habits, histories 
of current and previous illness, and medical treatment. 
We excluded 4992 participants from this study, com-
prising 1493 participants who were taking medications 
for hypertension, diabetes, dyslipidemia, or hyperurice-
mia, 1271 with alcohol consumption in amounts >70 g/
week for women (73) and >140  g/week for men (1198), 
857 participants with hepatitis B surface antigen (HBsAg) 
positivity, and 1758 missing information on age, sex, 
anthropometric assessment, components of metabolic 
syndrome, test results for HBsAg, or liver ultrasound 
scans. As some individuals met more than one exclusion 
criteria, the remaining available 10,761 participants (6901 
men and 3860 women) were included in our data analy-
sis. The fact that men accounted for 64.1 % of total par-
ticipants was in consistent with the proportion of male 
employees at WISCO. According to the Private Informa-
tion Protection Law, information that might identify sub-
jects was safeguarded by the Health Examination Center. 
This study was approved by the institutional review board 
of WISCO general Hospital. Because we only retrospec-
tively accessed a de-identified database for purposes of 
analysis, informed consent requirement was exempted by 
the institutional review board.
Anthropometric and biochemical measurements
Anthropometric measurements, including weight, 
height, and blood pressure (BP) were measured following 
standardized protocols from the World Health Organiza-
tion (WHO). Weight was measured with the participants 
wearing light clothing and height was measured with-
out shoes. BMI was calculated as weight (in kilograms) 
divided by the square of height (in meters). According to 
the WHO criteria for Asians [19], subjects were classified 
as normal weight (BMI of 18.5–22.9  kg/m2), and over-
weight/obesity (BMI ≥23  kg/m2). Participants’ seated 
BP was measured twice for every 5 min on the right arm 
after 5 min of rest by trained nurses with a sphygmoma-
nometer. The mean of the two readings was used in data 
analysis.
Overnight fasting (at least 8 h) blood samples were col-
lected from the antecubital vein of each individual. Bio-
chemical measurements, including assessment of fasting 
blood glucose (FBG), total cholesterol (TC), triglycer-
ides (TG), low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), alanine 
aminotransferase (ALT), and hepatitis viral antigen/anti-
body, were measured enzymatically on an autoanalyzer 
(Hitachi 7600, Ltd., Tokyo, Japan). All the blood meas-
urements were followed the same protocol.
Assessment of NAFLD
Ultrasound tests were performed by trained sonogra-
phers using a high-resolution, real-time scanner (model 
SSD-2000; Aloka Co., Ltd., Tokyo Japan). One experi-
enced radiologists used standard criteria in evaluating 
the images for the presence or absence of hepatic fat [20]. 
Generally, the diagnosis of fatty liver was based on the 
presence of stronger echoes in the hepatic parenchyma 
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compared with echoes in the kidney or spleen paren-
chyma [21].
Assessment of metabolic health status
Subjects were classified as metabolically at-risk by having 
any two of the following, consistent with the Adult Treat-
ment Panel-III (ATP III) metabolic syndrome definition [22] 
and with previous studies [23]: (1) High BP: systolic/dias-
tolic BP ≥130/85  mmHg, (2) High TG: TG ≥1.7  mmol/L 
(150  mg/dL), (3) High FBG: FBG ≥5.6  mmol/L (100  mg/
dL), (4) Low HDL-C: HDL-C ≥1.0/1.3 mmol/L (40/50 mg/
dL) for men/women. Waist circumference was not included 
in the definition because of collinearity with BMI. Subjects 
were classified as metabolically healthy by having zero or 
one risk factor. Participants were then categorized into four 
mutually body size phenotypes based on combinations of 
BMI categories and metabolic status: metabolically healthy 
and normal weight (MHNW), metabolically at-risk and 
normal weight (MANW), metabolically healthy and over-
weight or obese (MHOW), metabolically at-risk and over-
weight or obese (MAO).
According to the 2014 American Diabetes Asso-
ciation criteria [24], diabetes is defined as having FBG 
≥7.0 mmol/L.
Statistical analysis
All statistical analyses were conducted using SPSS soft-
ware (version 12.0 for windows; SPSS, Chicago, IL, USA). 
Variables were presented as means and standard errors 
(SE) for continuous variables and as percentages for cat-
egorical variables. Based on cross-classification of four 
body size phenotypes and the NAFLD status, participants 
were categorized into eight mutually exclusive groups 
(MHNW with or without NAFLD, MANW with or with-
out NAFLD, MHO with or without NAFLD, MAO with 
or without NAFLD). Differences in characteristics among 
these groups were verified by analysis of covariance 
or Cochran–Mantel–Haenszel Chi square statistics as 
appropriate. A post hoc (Scheffé method) multiple com-
parison was used to establish the differences between the 
groups, when necessary. Furthermore, a logistic regres-
sion model was used to estimate crude and adjusted odds 
ratios (OR) and corresponding 95  % confidence inter-
vals (CI) for the presence of NAFLD compared with the 
absence of NAFLD within each body size phenotype. The 
three models were as follows: Model 1 was an unadjusted 
model. Model 2 was adjusted for age, and sex. Model 3 
was additionally adjusted for TG/HDL-C (which was a 
good indicator of insulin resistance).
Venn diagram was constructed as a visual display of 
NAFLD and overweight/obesity based on BMI ≥23  kg/
m2. Similar processes were repeated for NAFLD and 
metabolic at-risk.
A logistic regression model was used to examine 
the joint associations of body size phenotypes and the 
NAFLD status with diabetes risk to determine whether 
the associations of body size phenotypes with diabetes 
differ based on the presence of NAFLD. Significance was 
accepted at a two-tailed P < 0.05.
Results
The prevalence of NAFLD in the MHNW, MHO, 
MANW, and MAO phenotype was 8.79, 31.72, 50.98, and 
76.19 %, respectively.
Table  1 described clinical characteristics of the study 
population stratified by body size phenotypes and 
NAFLD status. In each body size phenotype, subjects 
with NAFLD showed more atherogenic lipid profile as 
indicated by higher levels of TG, LDL-C, TG/HDL-C, 
and lower levels of HDL-C, and higher FBG levels than 
subjects without NAFLD (all P < 0.0001); Concentrations 
of atherogenic lipids and FBG were significantly higher 
in the MHNW/with NAFLD group (that is, participants 
with NAFLD alone) compared with the MHO/without 
NAFLD group (that is, participants with overweight/
obesity alone), implying that the associations of NAFLD 
with unfavorable lipid and glucose profiles were stronger 
than those of overweight/obesity. On the other hand, 
MHNW/with NAFLD group (that is, participants with 
NAFLD alone) had lower concentrations of atherogenic 
lipids than the MANW/without NAFLD group (that is, 
participants with metabolically at-risk alone), indicat-
ing that the association of NAFLD with unfavorable lipid 
profile was weaker than that of metabolically at-risk. For 
a given BMI status, the most favorable lipid profile and 
glucose levels were found in individuals with metaboli-
cally health/without NAFLD, and the worst atherogenic 
lipid profile and glucose levels were found in individuals 
with metabolically at-risk/with NAFLD: indicating that 
NAFLD and metabolically at-risk have synergistic effects 
on atherogenic lipid and glucose concentrations. For a 
given metabolic status, the differences in TG, TG/HDL-
C, HDL-C, and FBG between individuals with NAFLD 
and without NAFLD were more striking among normal-
weight subjects than among overweight/obese subjects, 
suggesting that NAFLD may reflect a more unfavorable 
distribution of body fat in normal-weight group.
We then assessed overlap between NAFLD and over-
weight/obesity diagnosed by BMI ≥23  kg/m2. Among 
those subjects (6699) with either NAFLD or overweight/
obesity, considerable participants (35.54  %) had over-
weight/obesity alone compared with 7.99 % with NAFLD 
alone. Moderate magnitude of overlap existed between 
NAFLD and overweight/obesity (56.47  %) (Fig.  1a). 
When analysis were stratified by the metabolic status, 
we found that the magnitude of overlap existed between 
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NAFLD and overweight/obesity was higher in metaboli-
cally at-risk subgroup (70.6 %) than that in metabolically 
healthy group (46.7 %) (The figure was not shown).
Similarly, we further assessed overlap between NAFLD 
and metabolically at-risk. Low magnitude of overlap existed 
between NAFLD and metabolically at-risk (39.91  %) 
(Fig.  1b). When analysis were stratified by the BMI cat-
egories, we found that the magnitude of overlap existed 
between NAFLD and metabolically at-risk was higher in 
overweight/obese subgroup (44.12 %) than that in normal-
weight group (20.88 %) (The figure was not shown).
Figure  2 illustrated how the three factors of interest 
(NAFLD, overweight/obesity, and metabolically at-risk) 
cluster together. Of the 7136 subjects who were identi-
fied to have any of the three factors, there were 1936 
(27.1  %) individuals with the simultaneous presence of 
the three factors, which occupied the largest proportion. 
The three factors occurred together in 56.16 % of diabetic 
individuals.
The ORs for diabetes risk from NAFLD compared with 
those without NAFLD were shown in Table  2. NAFLD 
was associated with diabetes in the MHNW and MHO 
phenotype, but the significance was lost in the MANW 
and MAO phenotype. ORs for diabetes from NAFLD 
compared with those without NAFLD in the MHNW 
and MHO phenotype were 2.10 (1.85–3.93) and 1.85 
(1.35–2.53) (model 2), respectively. These associations 
persisted after additional adjustment for TG/HDL-C, a 
good indicator of insulin resistance (model 3).
We then examined the joint effects of body size pheno-
types and the NAFLD status on the diabetes prevalence 
(Fig.  3a). The MHNW/without NAFLD group (0.77  %) 
had a similar frequency of diabetes to the MHO/with-
out NAFLD group (1.07 %), while MHNW/with NAFLD 
had a higher frequency of diabetes (2.11  %). The fre-
quency of diabetes in the MHO/without NAFLD group 
(1.07  %) was a little lower than that in the MHO/with 
NAFLD group (1.57  %). The frequency of diabetes was 
substantially higher in the MAO/without NAFLD group 
(15.79 %).
Multivariable-adjusted ORs for diabetes associated 
with overweight/obesity, metabolically at-risk, NAFLD, 
Table 1 Adjusted means of anthropometric and biochemical variables between groups with NAFLD and without NAFLD, 
stratified by overweight/obesity and metabolic status
Metabolically healthy and metabolically at-risk were defined in the definition section
Data are presented as mean (SE)
Data adjusted for age and sex
NAFLD nonalcoholic fatty liver disease, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, LDL low-density 
lipoprotein, HDL high-density lipoprotein, FPG fasting plasma glucose
* Data was unadjusted
BMI <23 kg/m2 BMI ≥23 kg/m2
Metabolically healthy Metabolically at-risk Metabolically health Metabolically at-risk
Without  
NAFLD
With NAFLD Without  
NAFLD
With NAFLD Without  
NAFLD
With NAFLD Without  
NAFLD
With NAFLD
N 3625 332 437 203 1776 1847 605 1936
Age (years)* 44.81 ± 0.25 48.77 ± 0.70 56.17 ± 0.69 56.41 ± 0.92 50.06 ± 0.34 50.40 ± 0.32 56.14 ± 0.59 53.61 ± 0.30
BMI (kg/m2) 20.59 ± 0.03 21.78 ± 0.06 21.26 ± 0.06 21.93 ± 0.07 24.75 ± 0.04 26.08 ± 0.05 25.10 ± 0.07 26.73 ± 0.06
SBP (mmHg) 116.12 ± 0.23 116.34 ± 0.75 128.48 ± 0.66 128.30 ± 0.96 120.67 ± 0.33 122.16 ± 0.33 130.23 ± 0.56 131.37 ± 0.32
DBP (mmHg) 72.90 ± 0.16 74.43 ± 0.53 81.30 ± 0.47 81.28 ± 0.68 76.30 ± 0.23 78.00 ± 0.23 82.56 ± 0.40 84.43 ± 0.23
ALT (U/L) 19.08 ± 0.23 26.58 ± 1.54 21.54 ± 0.88 25.14 ± 0.98 25.25 ± 0.83 30.32 ± 0.50 23.93 ± 0.60 35.19 ± 0.58
Total cholesterol 
(mmol/L)
4.40 ± 0.01 4.72 ± 0.05 4.58 ± 0.04 4.81 ± 0.06 4.58 ± 0.02 4.81 ± 0.02 4.74 ± 0.04 5.00 ± 0.02
Triglycerides 
(mmol/L)
0.86 ± 0.02 1.29 ± 0.07 1.78 ± 0.06 2.70 ± 0.09 1.04 ± 0.03 1.32 ± 0.03 1.96 ± 0.05 2.73 ± 0.03
LDL cholesterol 
(mmol/L)
2.64 ± 0.01 2.93 ± 0.04 2.73 ± 0.04 2.77 ± 0.05 2.85 ± 0.02 3.07 ± 0.02 2.84 ± 0.03 2.92 ± 0.02
HDL cholesterol 
(mmol/L)
1.54 ± 0.00 1.45 ± 0.02 1.31 ± 0.01 1.21 ± 0.02 1.43 ± 0.01 1.38 ± 0.01 1.23 ± 0.01 1.20 ± 0.01
Triglycerides/
HDL-C
0.58 ± 0.04 0.95 ± 0.12 1.55 ± 0.10 2.47 ± 0.15 0.76 ± 0.05 1.00 ± 0.05 1.86 ± 0.09 2.66 ± 0.05
FPG (mmol/L) 4.94 ± 0.02 5.58 ± 0.07 6.04 ± 0.06 6.45 ± 0.08 5.00 ± 0.03 5.53 ± 0.03 5.67 ± 0.05 5.98 ± 0.03
Uric acid 
(mmol/L)
273.14 ± 1.11 294.62 ± 3.61 289.96 ± 3.15 309.97 ± 4.61 291.76 ± 1.57 314.72 ± 1.56 303.25 ± 2.69 332.81 ± 1.53
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and their joint effects were displayed in Fig.  3b. Over-
weight/obesity was not associated with diabetes risk 
(1.1 [0.61–1.98]), whereas both metabolically at-risk and 
NAFLD increased the multivariable ORs for diabetes. 
Compared to the lowest risk group (the MHNW/with-
out NAFLD group), the MHNW/with NAFLD group, the 
MHO/without NAFLD group, the MHO/with NAFLD 
group, the MANW/without NAFLD group, the MANW/
with NAFLD group, the MAO/without NAFLD group, 
and the MAO/with NAFLD group had an multivariate-
adjusted OR of 2.23 (95  % CI 1.05–5.14), 1.10 (95  % CI 
0.61–1.98), 1.69 (95  % CI 1.01–2.53), 8.04 (95  % CI 
5.0–12.09), 14.63 (95  % CI 9.77–21.91), 16.57 (95  % CI 
10.47–26.24), and 23.22 (95  % CI 13.96–38.63) for dia-
betes risk, respectively. The trend for increasing ORs was 
more prominent among subjects with NAFLD (P for the 
interaction term body size phenotypes *NAFLD status 
<0.001).
Discussion
In the present study, we have described for the first time 
the clinical characteristics of the subjects stratified by 
body size phenotypes and NAFLD status. We found that 
NAFLD had a stronger association than overweight/
obesity while a weaker association than metabolically at-
risk with unfavorable lipid and glucose profiles. We also 
found that, for a given metabolic status, the associations 
of NAFLD with unfavorable lipid and glucose profiles 
Fig. 1 Venn Diagrams for concordance between obesity and nonalcoholic fatty liver disease (NAFLD) or between metabolically at-risk and NAFLD. 
Venn Diagram for a visual display of NAFLD and overweight/obesity based on BMI ≥23 kg/m2 in the whole population (a); Venn Diagram for a 
visual display of NAFLD and metabolically at-risk in the whole population (b). Metabolic risk indicates metabolically at-risk. Metabolically at-risk was 
defined in the Definition section
Fig. 2 Venn diagram for a visual display of how the three fac-
tors (overweight/obesity, NAFLD, and metabolically at-risk) cluster 
together. Metabolic risk indicates metabolically at-risk. Overweight/
obesity, NAFLD, and metabolically at-risk were defined in the defini-
tion Section
Table 2 Odds ratios for NAFLD-related risk of diabetes within each body size phenotype
Model 1 was an unadjusted model
Model 2 was adjusted for age, and sex
Model 3 was adjusted for all variables in model 2 plus triglycerides/HDL cholesterol
Metabolically healthy  
normal weight
Metabolically healthy  
overweight or obese




Model 1 2.77 (1.20–6.38) 1.74 (1.28–2.36) 1.52 (0.96–2.31) 1.48 (0.82–2.64)
Model 2 2.10 (1.85–3.93) 1.85 (1.35–2.53) 1.38 (0.89–2.14) 1.41 (0.78–2.54)
Model 3 2.58 (1.97–4.24) 1.83 (1.34–2.50) 1.38 (0.87–2.17) 1.61 (0.88–2.95)
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were more pronounced in normal-weight subjects than 
in overweight/obese subjects, emphasizing the impor-
tance of body fat distribution in the involvement of dia-
betes. In addition, we illustrated for the first time how the 
three factors (NAFLD, overweight/obesity, and metabolic 
at-risk) cluster together in both the whole population 
and the diabetic population. We found a significant dis-
sociation between these three factors in the whole popu-
lation, with only 27.1 % subjects with the presence of all 
the three factors occurring together. The simultaneous 
presence of the three factors was common (56.16  %) in 
diabetic population, suggesting the frequency and impor-
tance of the clustering of these three factors for diabe-
tes. Furthermore, we have examined the combined and 
separate associations of NAFLD, overweight/obesity, and 
metabolically at-risk with diabetes risk. We found that 
NAFLD and metabolically at-risk both independently 
associated with diabetes risk, with stronger associations 
seen for metabolically at-risk. We also found that the 
occurrence of all three factors together had the strongest 
association with diabetes.
Accumulating evidence shows that NAFLD is strongly 
associated with CVD risk factors [25, 26]. However, most 
of the studies regarding the association of NAFLD with 
CVD risk factors focused on obese subjects. Few studies 
have examined whether the diabetes risk associated with 
NAFLD is influenced by BMI categories or by metabolic 
status. A recent study that examined the associations of 
NAFLD with CVD risk factors according to BMI catego-
ries reported a more pronounced association in non-obese 
group than in obese group [8], indicating that the asso-
ciations of NAFLD with CVD risk factors may vary by a 
patient’s BMI status. The present analysis extended these 
findings to report the association between NAFLD and 
diabetes risk according to body size phenotypes (that is, 
cross-classification of BMI categories and metabolic sta-
tus). We found that, in the absence of metabolically at-
risk, NAFLD was associated with increased diabetes risk, 
Fig. 3 Combined effect of the presence of NAFLD and body size phenotypes on diabetes risk. Combined effect of the presence of NAFLD and 
body size phenotypes on the frequency of diabetes (a); Combined effect of the presence of NAFLD and body size phenotypes on the odds of dia-
betes (b). Odds ratios (95 % confidence intervals) of diabetes for participants categorized by cross-classification of four body size phenotypes and 
either the presence or absence of NAFLD were adjusted for age, sex, and triglycerides/HDL cholesterol. MHNW metabolically healthy normal weight, 
MHO metabolically healthy overweight or obese, MANW metabolically at-risk normal weight, and MAO metabolically at-risk overweight or obese. 
Each of the four body size phenotypes was defined in the definition section
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regardless of obesity status. However, the association was 
more pronounced in non-obese group than in overweight/
obese group. In the presence of metabolically at-risk, the 
significant association between NAFLD and diabetes was 
lost. Taken together, the association between NAFLD and 
diabetes varies both by a patient’s BMI category and meta-
bolic status. Although explanations for the results remain 
to be elucidated, it is probably related to differences in 
regional adipose tissue distribution [27]. BMI provides a 
general measure of obesity but cannot discriminate among 
visceral, ectopic, and subcutaneous fat accumulation. It is 
possible that visceral fat accumulation or ectopic fat depo-
sition in tissues such as liver and pancreas have a stronger 
relationship with obesity-associated comorbidities than 
BMI [27–29]. The anatomic, cellular and molecular fea-
tures of visceral or ectopic fat define the obesity-associated 
outcomes [27]. The significance of other factors such as the 
generational transfer of metabolic phenotype or NAFLD 
to offspring which occurred partly through epigenetic 
changes or micro-biota [30], and sleep apnea [31] may also 
explain our results. Obstructive sleep apnea, which often 
coexists with obesity, can mediate fatty pancreas through 
tissue hypoxia and lipolysis [31]. Evidence shows that fatty 
pancreas is a sensitive marker for NAFLD [32], and meta-
bolic syndrome [29].
The concomitant presence of overweight/obesity, 
NAFLD, and metabolically at-risk is common [33, 34]. 
However, in the present study, we observed considerable 
dissociation between the three risk factors, which might 
explain the different macrovascular complication pheno-
types in diabetic patients [35]. According to the adipo-
cyte expandability hypothesis, the subcutaneous fat acts 
as a metabolic sink, buffering dietary fat to limit their 
deposition in other organs [36–38]. When increased 
energy intake exceeded the subcutaneous adipose tissue’s 
capacity for buffering, lipid will be ectopically deposited 
in ectopic sites such as liver and the visceral component 
of abdominal fat. The adipocyte overflow hypothesis 
infers that some obese individuals, referred as metaboli-
cally healthy obesity, are characterized by increased lipid 
deposition in subcutaneous depot, and thus are pro-
tected against obesity-related metabolic disturbances. 
Conversely, for some obese individuals, called metaboli-
cally at-risk obesity, subcutaneous adipose tissue may 
reach its maximal storage capacity, causing an overflow 
of fatty acids into ectopic sites, inducing lipotoxicities 
that in turn lead to diabetes. The remarkable variation in 
metabolic status for any given BMI observed in a study 
[39] and the remarkable variation in metabolic status and 
NAFLD status for any given BMI category observed in 
our present study further supported the notion.
The dissociation between the three factors results in 
different combinations of the three factors, conferring 
differential odds of diabetes and different macrovascu-
lar complication phenotypes in diabetic patients [35], as 
each of the three factors act via different pathogenetic 
mechanisms to increase diabetes risk. It is well known 
that increased BMI is associated with pro-inflammatory 
molecules and atherogenic lipid biomarkers, which are 
capable of inhibiting insulin signaling. NAFLD increases 
diabetes risk via mechanisms that increase the secretion 
of hepatokines such as fetuin-A, and plasminogen-acti-
vator inhibitor-1 [40], increase gluconeogenesis, decrease 
glycogen synthesis, and inhibit insulin signaling [41, 
42]; Metabolically at-risk is closely correlated with vis-
ceral adiposity [43]. Visceral adiposity, having a greater 
endocrine activity than does subcutaneous fat [27], may 
affect risk of diabetes via an effect on the secretion of 
pro-inflammatory molecules capable of inducing insulin 
resistance, increased rates of lipolysis that induce exces-
sive free fatty acid and resistine release and thus leading 
to lipotoxicity and insulin resistance.
Although we observed greater ORs for diabetes asso-
ciated with metabolically at-risk compared with NAFLD, 
being NAFLD was associated with poorer lipid and glu-
cose profiles within the same metabolic status. Among 
both the normal-weight group and overweight/obese 
group, the most favorable lipid and glucose profiles 
were found in subjects with metabolically health/with-
out NAFLD. In addition, there was a marked increase in 
odds of diabetes in subjects with metabolically at-risk/
with NAFLD, regardless of obesity status. The fact that 
metabolically at-risk and NAFLD have independent 
effects on each other and have synergistic effects on dia-
betes risk suggests that targeted specific approaches to 
preventing visceral fat or ectopic fat accumulation or to 
reversing the visceral fat or ectopic fat accumulation may 
have a considerable impact on decreasing diabetes risk. 
The presence of all the three factors occurring together, 
which was the most frequent combination of the three 
factors among diabetic subjects, had the strongest asso-
ciation with diabetes, indicating that an optimal preven-
tion strategy for diabetes should emphasize amelioration 
of the effects of each of the three factors.
Several prospective cohort studies suggest that MHO 
phenotype might be associated with a nonsignificant or 
significant increased risk of diabetes incidence [33, 44–
47]. Until now, there is no consensus on how to define 
the MHO phenotype. The absence of a universal defini-
tion for MHO phenotype might result in substantial mis-
classification of individuals who actually have a high-risk 
phenotype as having a low-risk phenotype. Our results 
that MHO without NAFLD group did not have a sig-
nificantly increased OR for diabetes and that MHO with 
NAFLD group had an OR of 1.69 (95 % CI 1.01–2.53) for 
diabetes suggest that NAFLD could play important roles 
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in differentiating obese phenotypes at high risk of diabe-
tes. In the present study, 31.72 % MHO individuals suf-
fered from NAFLD. Hence, adding information on the 
presence of NAFLD into the assessment of MHO phe-
notype would contribute to assess whether an individual 
was actually in a metabolically healthy state. In addition, 
in the obesity state, metabolic at-risk favors the storage 
of fat in the liver and heralds a higher risk of nonalco-
holic steatohepatitis and advanced fibrosis [48]. Nonalco-
holic steatohepatitis forecasts an increased risk of CVD 
mortality [49]. Hence, exploring how the three factors 
(NAFLD, overweight/obesity, and metabolic at-risk) clus-
ter together could help to early identification of patients 
with nonalcoholic steatohepatitis and might have clinical 
implications for developing diagnostic and therapeutic 
strategies targeting CVD.
There are several limitations. The cross-sectional 
design implies that no causal relationship can be drawn. 
We only had data on Chinese adults comprised of 
selected populations (industrial employees and retired 
workers) with a preponderance of men, thus, extrapolat-
ing results to the Chinese general population or to other 
racial or ethnic population should be interpreted cau-
tiously. Since NAFLD was diagnosed by ultrasonography, 
which is a reasonably accurate technique for detecting 
modest amounts of liver fat (>30 % liver fat infiltration), 
participants with minor amounts of fatty infiltration 
might not have been captured. That NAFLD was not 
confirmed by liver biopsy was also a limitation. A stand-
ard 75-g oral glucose tolerance test was not performed, 
which might suggest an underestimation of the diabetes 
prevalence.
Conclusions
The association of NAFLD with diabetes is more pro-
nounced in normal-weight individuals than in over-
weight/obese individuals among participants without 
metabolic at-risk. There is a significant dissociation of 
the three factors (overweight/obesity, NAFLD, and meta-
bolically at-risk) in the whole population, while the three 
factors commonly occur together in diabetic individuals. 
Of the three factors, overweight/obesity had the weak-
est association with diabetes and metabolically at-risk 
had the strongest association. The presence of all three 
risk factors occurring together strikingly and markedly 
increases the diabetes risk. NAFLD should be consid-
ered as a more meaningful predictor of diabetes in MHO 
individuals.
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